ArticleEuropean journal of nuclear medicine and molecular imaging2026
Early post-infarct fibroblast activation protein-targeted PET/CT with
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundFibroblast activation protein (FAP)-targeted PET/CT with radiolabeled FAPIs enables noninvasive visualization of fibroblast activity following ST-segment elevation myocardial infarction (STEMI). However, the prognostic implications of myocardial FAPI uptake remain insufficiently characterized.
objectivesThis prospective study aimed to evaluate the prognostic value of
methodsWithin six days after successful PPCI, patients underwent
resultsA total of 50 STEMI patients were finally included in this study. Baseline FAV showed a positive linear correlation with one-year LVEDD (r = 0.298, p = 0.036) and independently predicted LVEDD > 50 mm (OR 1.022, 95% CI 1.007-1.038, p = 0.004). In adjusted analysis, each unit increase in FAV was associated with a 1.1% higher risk of MACEs. A nonlinear relationship was observed, with FAV ≤ 81.34 corresponding to a 5% increase in MACE risk per unit rise (HR 1.05, 95% CI 1.003-1.098, p = 0.035). Using an optimal FAV cutoff of 51.6, patients with high FAV had significantly more MACEs than those with low FAV (47.22% vs. 14.29%, p = 0.031). Incorporating dichotomized FAV into a conventional clinical model was associated with improved discrimination of two-year MACEs (AUC 0.84 vs. 0.70, p = 0.021) and provided significant net reclassification (NRI 0.506, p < 0.001) and integrated discrimination improvement (IDI 0.212, p < 0.001).
conclusionsIn STEMI patients with preserved LVEF, early fibroblast activation measured by ⁶⁸Ga FAPI 46 PET/CT is associated with subsequent left ventricular remodeling. FAV may provide incremental prognostic value beyond traditional risk factors. These findings are exploratory, and warrant validation in larger, multicenter cohorts and comparisons with other relevant imaging methods.
Indexed as
Identifiers
42477144What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.